Aurora Cannabis Inc.

TSX:ACB.TO

Drug Manufacturers - Specialty & Generic

Healthcare
$6.31 +0.48%

+$0.02 today

Market cap
$414.85M
Beta
1.34
P/E (TTM)
-3.2
EPS (TTM)
-$1.31
52W Low $3.77High $9.33

Volume 0.32M

Average 0.42M

ACB.TO Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Aurora Cannabis Inc.TSX: ACB.TO

Stock-Based Compensation · Q4 FY2026 · quarter ended Mar 2026

Stock-based compensation declines year over year

Q4 FY2026 stock-based compensation of CA$689K fell 71.1% year over year, behind the -36.7% change in trailing-twelve-month stock-based compensation. Over 3 fiscal years it compounded at -24.4% a year.

Context

  • Stock-based compensation amounted to 2.3% of revenue in FY2026, down 1.1 pp from a year earlier.
  • Stock-based compensation increased in 0 of the last 3 fiscal years.
  • FY2026 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -71.1% toward the trailing-twelve-month pace of -36.7%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
CA$689K+225.0% QoQ
Last fiscal yearMar 2026
CA$7.29M-36.7% YoY
LTMMar 2026
CA$7.29M-36.7% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-71.1%——
1 year-36.7%——
3-year CAGR-24.4%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

CAD · from the cash flow

Latest · FY2026
7.29M CAD
Year-over-year change
-36.7%
4-year CAGR
-14.7%

Stock-Based Compensation vs competitors

How ACB.TO compares with its peers on the latest reported figures

  • Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -36.7% is the 7th highest of 8, against a peer median of +5.0%.
  • Stock-based compensation amounts to 2.3% of revenue for ACB.TO, versus a peer median of 3.0%.
ACB.TO Competitors
Stock-Based Compensation for ACB.TO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ACB.TOAurora Cannabis Inc.LTM Mar 2026CA$7.29M CAD-36.7%-24.4%2.3%
FRX.TOFennec Pharmaceuticals Inc.LTM Mar 2026$7.23M USD+54.8%+18.6%14.1%
WEED.TOCanopy Growth CorporationLTM Mar 2026CA$5.06M CAD+220.3%-44.8%1.6%
XLY.TOAuxly Cannabis Group Inc.LTM Mar 2026CA$4.81M CAD+5.0%+9.4%3.0%
TSND.TOTerrAscend Corp.LTM Mar 2026$4.38M USD-55.0%-25.6%1.7%
OGI.TOOrganiGram Holdings Inc.LTM Mar 2026CA$3.45M CAD-36.6%—1.3%
EDT.TOSpectral Medical Inc.LTM Mar 2026CA$2.48M CAD-10.1%+21.0%89.8%
CPH.TOCipher Pharmaceuticals Inc.LTM Mar 2026$1.8M USD+64.7%+62.8%3.5%
Peer median (excluding ACB.TO) —+5.0%+14.0%3.0%

Competitors are the stored peer set for ACB.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

CAD
Metric
FY2022
Jun 2022
FY2023
Mar 2023
FY2024
Mar 2024
FY2025
Mar 2025
FY2026
Mar 2026
Net Income(1.72B)(265.33M)(59.05M)15.76M(58.62M)
Depreciation & Amortization93.66M43.57M33.07M22.55M14.19M
Deferred Income Tax(2.19M)(18.4M)(1.67M)(3.19M)55K
Stock-Based Compensation13.76M16.89M12.72M11.52M7.29M
Change in Working Capital52.65M(25.12M)(15.63M)10.21M(9.21M)
Accounts Receivables18.34M5.53M(4.33M)5.24M(8.15M)
Inventory21.07M49.03M3.62M(15.05M)7.44M
Accounts Payables6.77M(8.06M)(15.7M)14.91M(8.04M)
Other Working Capital6.48M(71.61M)790K5.11M(9.21M)
Other Non-Cash Items1.45B190.11M(37.96M)(40.85M)54.32M
Operating Cash Flow(110.27M)(115.82M)(68.51M)16.01M(13.51M)
Capital Expenditures(32.21M)(12.13M)(16.96M)(18.86M)(22.55M)
Acquisitions (Net)(23.42M)(18.54M)(5.55M)01.1M
Purchases of Investments00000
Sales of Investments03.36M4.99M5.49M0
Other Investing Activities19.46M16K12.02M(956K)(51.98M)
Investing Cash Flow(36.17M)(27.29M)(5.49M)(14.33M)(73.43M)
Debt Repayment(170.83M)—(85.76M)(805K)(5.02M)
Common Stock Issued350.19M73.19M37.93M00
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(31.58M)(95.21M)(89K)689K(154K)
Financing Cash Flow147.78M(56.48M)(47.92M)(116K)9.76M
Effect of Forex Changes15.01M15.54M297K264K4.33M
Net Change in Cash16.35M(140.01M)(121.5M)1.83M(72.85M)
Free Cash Flow(142.48M)(127.95M)(85.46M)(2.85M)(36.06M)

Aurora Cannabis Inc.

TSX:ACB.TO

Intrinsic Alpha fair value

Locked

Current Price

$6.31

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.